DECIDE DECIDE ( Diagnostic Enhancement of Confidence by an International Distributed Environment ) David Manset – maatG France DECIDE SA Coordinator Live Demonstration at the EGI User Forum – Vilnius, Lithuania David Manset, maatG France Isabella Castiglioni, CNR/IBFM Andrea Schenone, University of Genoa And On Behalf of DECIDE Project Consortium Valeria Ardizzone - COMETA DECIDE Technical Coordinator Presenters

Consortium David Manset - maatG EGI User Forum Demonstration 2 1 CONSORTIUM GARR Italy 3 CONSORZIO COMETA Italy 2 CNR 6 UNIVERSITY OF GENOA - UNIGE Italy 7 UNIVERSITY OF FOGGIA - UNIFG Italy 9 MAAT FRANCE - maat G France 10 IMPERIAL COLLEGE– United Kingdom 11 UNIWERSYTET WARSZAWSKI - Poland 4 FATEBENEFRATELLI - Italy 5 UNIVERSITY SAN RAFFAELE - Italy 8 FONDAZIONE SDN - Italy 12 CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE - France 13 ALZHEIMER EUROPE - Luxembourg To provide the Neuroscientific and Medical community with a dedicated Grid-based e- Infrastructure To deploy a secure and user-friendly service for the early diagnosis and research on dementia and other brain diseases To validate the e-Infrastructure and the services To propose a long-term vision for the sustainability of the e-Infrastructure To disseminate the results and provide training programmes Objectives

e-Infrastructure David Manset - maatG EGI User Forum Demonstration CONNECTIVITY. INFRASTRUCTURE GRID INFRASTRUCTURE DECIDE PLATFORM GEANT & NRENs Internet Network High-capacity bandwidths, Production sites, From 100 Mbps to 1Gbps Grid-based Infrastructure EGI gLite middleware, Builds on neuGRID/outGRID, ROC certified resources, QoS defined by SLA, 10 Grid Sites, 6 Production, 4 Pre-Production, More than 600 dedicated CPU cores, Can expand to LSGC resources Production quality e-Infrastructure to service translational research

Early Diagnostic of AD David Manset - maatG EGI User Forum Demonstration 4 Hypocaptation of radioactive tracer (FDG) as measured from PET imaging Yellow regions identified by SPM in the MCI phase (retrosplenial cortex and bilateral temporal-parietal) are typical AD pattern Alzheimer’s Disease (AD) marker SPM shows AD progression, From Mild Cognitive Impairment (MCI) to AD, Marker highlights typical spatial patterns, Allows measuring disease evolution, Used to diagnose disease stage, Interesting for early diagnostic of AD, Adapted treatment and care Patient with Mild Cognitive Impairment (MCI) and progressed in AD after 1 year Marker specificities Requires lots of norma-controls (i.e. healthy patients) data, The more data, the more accurate, Norma-control is rare data, As it requires exposing patients to radioactive material, Strong ethical regulations at national/regional levels, e.g. no children data etc

Early Diagnostic of AD David Manset - maatG EGI User Forum Demonstration 5 Why the Grid? Grid as a federated database of norma-controls across participating centers Grid allows sharing without moving/copying data, Single virtual repository of such rare data Grid provides computational power to access, process and store diagnostic results, Norma-controls are re- processed each time a diagnostic is requested, SPM expected to be run 5- 10x/year/patient SPM processing steps. (1) Spatial Normalization allows comparing images (2) Checks patient against normal parameters distribution (3) Statistically infers data to highlight regions of hypo- captations

e-Infrastructure David Manset - maatG EGI User Forum Demonstration 6 LifeRay-based Web portal Diagnostic services as Portlets User-friendly access Simple login + password Single Sign On + Shibboleth Multiple IdP security architecture Robot-certificate mapping Demonstration: